Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II
Saved in:
| Published in: | Dermatology and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II
- Cost–Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan
- Factors Associated With Quality of Life and Treatment Practice Among Melasma Patients in Nepal
- Sex Differences in Patient-Reported Outcomes Among People Living With HIV Switching to an Oral Dual Therapy: Results From the PROBI Study
- Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis
- Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)
- Sebum-Selective 1,726-nm Laser Therapy for Papulopustular Rosacea Associated with Demodex Mite Proliferation: A Case Report